Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 With Standard of Care in NSCLC and Squamous Oesophageal Cancer
NCT04908111Phase 2Suspended
- Sponsor
- Cancer Research UK
- Start
- Oct 2021
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of VTP-600, MVA-MAGEA3, MVA-NYESO in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the esophagus (ESCC), sponsored by Cancer Research UK. Started Oct 2021; status: suspended.
02
Drugs
VTP-600MVA-MAGEA3MVA-NYESO
03
Conditions
non-small cell lung cancer (NSCLC)squamous cell carcinoma of the esophagus (ESCC)
Beyond the preview
Go deeper on NCT04908111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908111.